Cash & equivalents increased 59.1%
Cash & equivalents changed +59.1% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Cash & equivalents changed +59.1% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Net income changed -40.1% from the comparable as-filed period.
Operating income changed -22.3% from the comparable as-filed period.
Capital expenditure changed -17.4% from the comparable as-filed period.
Operating margin changed -225 basis points from the comparable as-filed period.
Research & development changed +14.0% from the comparable as-filed period.
Capex / revenue changed -85 basis points from the comparable as-filed period.
Gross margin changed -30 basis points from the comparable as-filed period.
Gross profit changed +1.6% from the comparable as-filed period.
Inventory changed -1.3% from the comparable as-filed period.
Revenue changed +3.3% from the comparable as-filed period.
Selling, general & administrative changed -4.8% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.